Key facts
- BioHive’s last known valuation is $7.5M (Jan 2026).
- It has raised $2.8M; the latest was Early Stage VC ($2.8M) in Jan 2026.
- Notable investors include Kima Ventures, Super Capital, Better Angle, 50 Partners, Genopole — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BioHive
- ·The full record, as it builds
Funding rounds
No funding rounds for BioHive are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioHive
Developer of skin organoids technology designed for pathological modeling on skin organoids and preclinical testing of molecules. The company leverages advanced analytics, particularly high-resolution imaging, to provide in vitro models, offers access to a proprietary biobank of customizable organoids, and enhances the reliability of preclinical research, enabling cosmetic, pharmaceutical, and nutraceutical sectors to conduct precise disease modeling for genetic and inflammatory conditions, as well as the evaluation of active compounds on both healthy and pathological skin organoids.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2023
- Employees
- 2
- Website
- biohive-innovations.com/
- Ownership
- Privately Held (backing)
BioHive doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioHive shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioHive in its N-PORT filings yet. We sweep new filings monthly.